DEVELOPING RECOMMENDATIONS FOR PREVENTING AND TREATING PRENATAL OPIOID USE DISORDERS.

SEC. 3. DEVELOPING RECOMMENDATIONS FOR PREVENTING AND TREATING PRENATAL OPIOID USE DISORDERS. (a) In General.—The Secretary shall conduct a study and develop recommendations for preventing and treating prenatal opioid use disorders, including the effects of such disorders on infants. In carrying out this subsection the Secretary shall— (1) take into consideration— (A) the review and strategy conducted and developed under section 2; and (B) the lessons learned from previous opioid epidemics; and (2) solicit input from States, localities, and Federally recognized Indian tribes or tribal organizations (as defined in the Indian Self-Determination and Education Assistance Act (25 U.S.C. 450b)), and nongovernmental entities, including organizations representing patients, health care providers, hospitals, other treatment facilities, and other entities, as appropriate. (b) Report.—Not later than 18 months after the date of enactment of this Act, the Secretary shall make available on the appropriate Internet Website of the Department of Health and Human Services a report on the recommendations under subsection (a). Such report shall address each of the issues described in subsection (c). (c) Contents.—The recommendations described in subsection (a) and the report under subsection (b) shall include— (1) a comprehensive assessment of existing research with respect to the prevention, identification, treatment, and long-term outcomes of neonatal abstinence syndrome, including the identification and treatment of pregnant women or women who may become pregnant who use opioids or have opioid use disorders; (2) an evaluation of— (A) the causes of, and risk factors for, opioid use disorders among women of reproductive age, including pregnant women; (B) the barriers to identifying and treating opioid use disorders among women of reproductive age, including pregnant and postpartum women and women with young children; (C) current practices in the health care system to respond to, and treat, pregnant women with opioid use disorders and infants affected by such disorders; (D) medically indicated uses of opioids during pregnancy; (E) access to treatment for opioid use disorders in pregnant and postpartum women; and (F) access to treatment for infants with neonatal abstinence syndrome; and (G) differences in prenatal opioid use and use disorders in pregnant women between demographic groups; and (3) recommendations on— (A) preventing, identifying, and treating the effects of prenatal opioid use on infants; (B) treating pregnant women who have opioid use disorders; (C) preventing opioid use disorders among women of reproductive age, including pregnant women, who may be at risk of developing opioid use disorders; and (D) reducing disparities in opioid use disorders among pregnant women.